Clinical trials: Moderate to Severe Rheumatoid Arthritis
Rheumatoid Arthritis
Long-term Observational Study to Evaluation the Safety of FURESTEM-RA Inj(K0202)
Long-term Observational Study to Evaluation the Safety of FURESTEM-RA Inj(K0202)
- Trial name
- NCT04134169
- Testing
- Not applicable(observational study)
- Where
- South Korea
- Volunteers
- 28 people
- Sponsor
- Kang Stem Biotech Co., Ltd.
Rheumatoid Arthritis
A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs)
This 3 arm randomized open label study will evaluate the safety, tolerability and efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis, who have had inadequate response to or are unable to…
- Trial name
- NCT00891020
- Testing
- tocilizumab [RoActemra/Actemra], Nonbiologic DMARDs of investigator's choice
- Where
- 227 sites in United States
- Volunteers
- 886 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)
The study objective of Period 1 of this study is to compare the safety and efficacy (signs and symptoms) of upadacitinib 30 mg once daily (QD) alone and upadacitinib 15 mg QD alone versus continuing MTX alone adults with…
- Trial name
- NCT02706951
- Testing
- Methotrexate, Upadacitinib
- Where
- 153 sites in United States, Argentina and 23 more
- Volunteers
- 648 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
A Study to Compare Efficacy and Safety of CT-P17 With Humira in Patients With Active Rheumatoid Arthritis
This is a Phase III Study to Compare Efficacy and Safety of CT-P17 with Humira in Patients With Active Rheumatoid Arthritis
- Trial name
- NCT03789292
- Testing
- CT-P17 SC, Humira SC
- Where
- Bulgaria
- Volunteers
- 648 people
- Sponsor
- Celltrion
Rheumatoid Arthritis
Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Active, Stable, Moderate to Severe Rheumatoid Arthritis
Study X052070 will evaluate the safety and pharmacokinetics (PK) of XOMA 052 administered to patients with active, stable, moderate to severe rheumatoid arthritis (RA).
- Trial name
- NCT00777816
- Testing
- XOMA 052
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- XOMA (US) LLC
Rheumatoid Arthritis
Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA
This is a Phase 2 study to investigate the safety, tolerability, PK, and PD of ATI-450 plus methotrexate versus methotrexate alone in patients with moderate to severe RA.
- Trial name
- NCT04247815
- Testing
- ATI-450, Methotrexate
- Where
- 5 sites in United States
- Volunteers
- 25 people
- Sponsor
- Aclaris Therapeutics, Inc.
Rheumatoid Arthritis
Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid Arthritis
The study aims to evaluate the predictability of early response to Certolizumab pegol in combination with Methotrexate at one year in patients with moderate to severe rheumatoid arthritis.
- Trial name
- SPEED (NCT01443364)
- Testing
- Certolizumab pegol
- Where
- 18 sites in Italy
- Volunteers
- 132 people
- Sponsor
- UCB Italy s.p.a.
Rheumatoid Arthritis
A Long-Term Extension Study of WA22762 to Evaluate Safety and Efficacy of Subcutaneous Tocilizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA).
This multicenter, open-label, single arm, interventional, long-term extension (LTE) study will evaluate the safety and efficacy of tocilizumab (TCZ, RoActemra/Actemra) in French participants with moderate to severe RA who have…
- Trial name
- NCT01734993
- Testing
- Tocilizumab
- Where
- 6 sites in France
- Volunteers
- 11 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis, Arthritis, Rheumatoid
A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis
The purpose of this study is to determine the safety and tolerability of imvotamab in patients with moderate to severe rheumatoid arthritis who have failed prior therapies.
- Conditions
- Rheumatoid Arthritis, Arthritis, Rheumatoid, Arthritis
- Trial name
- NCT06087406
- Testing
- Imvotamab
- Where
- 18 sites in United States, Poland
- Volunteers
- 33 people
- Sponsor
- IGM Biosciences, Inc.
Rheumatoid Arthritis
A Study of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis
The primary objective of this study is to evaluate the efficacy of 3 subcutaneous doses of mavrilimumab compared with placebo in combination with methotrexate (MTX) in subjects with moderate-to-severe adult onset Rheumatoid…
- Trial name
- NCT01706926
- Testing
- Mavrilimumab 30 mg, Mavrilimumab 100 mg, Mavrilimumab 150 mg
- Where
- 42 sites in Argentina, Bulgaria and 12 more
- Volunteers
- 420 people
- Sponsor
- MedImmune LLC
Arthritis, Rheumatoid
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
The primary objective of this trial is to evaluate the long-term safety of BI 695500 in adult patients with moderately to severely active rheumatoid arthritis (RA) who have successfully completed treatment in Trial 1301.1.
- Trial name
- NCT01955733
- Testing
- BI 695500
- Where
- 43 sites in United States, Belgium and 7 more
- Volunteers
- 91 people
- Sponsor
- Boehringer Ingelheim
Arthritis, Rheumatoid
Safety and Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Efficacy of Repeat Doses of GSK2982772 in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)
This study is the first study with GSK2982772, a receptor-interacting protein-1 (RIP1) kinase inhibitor, in subjects with moderate to severe RA who are currently being treated with disease modifying anti-rheumatic drugs (DMARDs).
- Trial name
- NCT02858492
- Testing
- GSK2982772 60 mg
- Where
- 16 sites in Germany, Italy and 4 more
- Volunteers
- 52 people
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis (RA)
Safety and Efficacy of TollB-001 Tablets in Moderate to Severe Rheumatoid Arthritis
The goal of this study is to evaluate the safety, pharmacokinetic (PK) characteristics, and preliminary efficacy of a new oral chemical drug in : adults aged 18-70 years (male or female) with moderate to severe active rheumatoid…
- Trial name
- NCT07408024
- Testing
- TollB-001
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Toll Biotech Co. Ltd. (Beijing)
Rheumatoid Arthritis
A Study to Evaluate the Safety and Efficacy of SM03 in Patients With Rheumatoid Arthritis Receiving Methotrexate
This study evaluated the safety and efficacy of SM03 compared to placebo in patients with active rheumatoid arthritis(RA) receiving methotrexate
- Trial name
- NCT04192617
- Testing
- SM03, Methotrexate
- Where
- China
- Volunteers
- 156 people
- Sponsor
- SinoMab BioScience Ltd
Rheumatoid Arthritis
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
This randomized, double-blind, parallel group study will assess the safety, disease remission, and prevention of structural joint damage in patients with early moderate to severe rheumatoid arthritis treated with tocilizumab as…
- Trial name
- NCT01007435
- Testing
- Tocilizumab, Methotrexate
- Where
- 236 sites in United States, Argentina and 34 more
- Volunteers
- 1,162 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
An Observational Study to Assess the Impact of Upadacitinib in Adult Hungarian Participants With Moderate to Severe Rheumatoid Arthritis (RA) in Real-World Practice
Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. Despite the range of treatment options for RA steadily increasing, many patients remain sub-optimally…
- Trial name
- UPDATE (NCT05327920)
- Where
- 8 sites in Hungary
- Volunteers
- 93 people
- Sponsor
- AbbVie
Arthritis, Rheumatoid
Observational Study to Determine How Physicians Make Treatment Decisions in Patients Treated With Tofacitinib for Moderate to Severe Active Rheumatoid Arthritis
This non-interventional study aims to identify key factors that are driving treatment decisions by rheumatologists in the treatment of rheumatoid arthritis (RA) patients starting treatment with Tofacitinib in a real world setting.
- Trial name
- ESCALATE-RA (NCT03387423)
- Testing
- Tofacitinib
- Where
- 91 sites in Germany
- Volunteers
- 1,459 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
A Study in Patients With Moderate to Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations of RoActemra/Actemra (Tocilizumab) Treatment
This multi-center, randomized, parallel-group, active-controlled, open-label study will evaluate the safety and efficacy of a shortened RoActemra/Actemra (tocilizumab) infusion time compared to the normal infusion time.
- Trial name
- NCT01468077
- Testing
- Tocilizumab
- Where
- 8 sites in Denmark, Iceland
- Volunteers
- 47 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate
The purpose of this study is to determine the safety, tolerability and efficacy of natalizumab in subjects diagnosed with moderate to severe rheumatoid arthritis (RA) receiving concomitant treatment with methotrexate (MTX).
- Trial name
- NCT00083759
- Testing
- natalizumab
- Where
- 12 sites in United States, Canada
- Volunteers
- 299 people
- Sponsor
- Biogen
Rheumatoid Arthritis
A Study Comparing SB2 to Remicade® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
This is a randomized, double-blind, parallel group, multicentre clinical study to evaluate the efficacy, safety, pharmacokinetics and immunogenicity of SB2 compared to Remicade in subjects with moderate to severe Rheumatoid…
- Trial name
- NCT01936181
- Testing
- Remicade (infliximab), SB2 (proposed biosimilar to infliximab)
- Where
- 2 sites in Bulgaria, Lithuania
- Volunteers
- 584 people
- Sponsor
- Samsung Bioepis Co., Ltd.